Mark Kotter, CEO fi­nal­ly de­tails cell ther­a­py pipeline for re­gen­er­a­tive treat­ment, with ini­tial fo­cus on liv­er has lift­ed the cur­tain on its ear­ly pipeline of re­gen­er­a­tive med­i­cine can­di­dates made us­ing its cell pro­gram­ming tech­nol­o­gy, which is in­tend­ed to de­ter­min­is­ti­cal­ly trans­form stem cells in­to ma­ture cells.

The UK-based com­pa­ny’s lead cell ther­a­py pro­gram, bb­HEP01, com­pris­es en­cap­su­lat­ed he­pa­to­cyte-like cells made us­ing its op­ti-ox tech­nol­o­gy. had pre­vi­ous­ly ex­pressed am­bi­tions to move in­to cell ther­a­py R&D us­ing op­ti-ox but had not un­veiled the specifics of its pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.